Inhibitory effect of Azone® (1-dodecylazacycloheptan-2-one) on herpes simplex virus. In vivo and in vitro studies

M. F. Leonard, A. Kumar, Dennis L Murray, D. C. Beaman

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Enhanced activity of antiviral agents, when mixed with a penetration enhancer like Azone® (1-dodecylazacycloheptan-2-one) in topical preparations, is well-recognized. These studies were undertaken to investigate whether Azone, per se, has any activity against herpes simplex (HSV) type 1 and type 2 viruses. When HSV-1 and HSV-2 were mixed with 5, 10 and 20% Azone, there was a 1-4.5 log 10 decrease in virus titers. The efficacy of 5 and 10% Azone applied topically was evaluated during the treatment of HSV-1 cutaneous infections in guinea pigs. HSV-1 infection was produced by intradermally inoculating guinea pigs with 10 7.7 HSV-l/ml. The mean number of lesions per site was reduced by more than 50% in Azone-treated sites as compared to no treatment (control) sites (p < 0.01). Similarly, the surface area of each lesion in the Azone-treated sites was only 40% of that seen in control sites (p < 0.001). More than 80% of the lesions on Azone-treated sites healed by day 4 as compared to only 3% on control sites (p < 0.001). These data indicate that Azone, a lipophilic chemical, may have antiviral properties when used topically.

Original languageEnglish (US)
Pages (from-to)151-156
Number of pages6
JournalChemotherapy
Volume33
Issue number2
DOIs
StatePublished - Jan 1 1987

Fingerprint

Simplexvirus
Human Herpesvirus 1
Human Herpesvirus 2
Antiviral Agents
Guinea Pigs
Herpes Simplex
In Vitro Techniques
laurocapram
Infection
Viral Load
Viruses
Skin

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Inhibitory effect of Azone® (1-dodecylazacycloheptan-2-one) on herpes simplex virus. In vivo and in vitro studies. / Leonard, M. F.; Kumar, A.; Murray, Dennis L; Beaman, D. C.

In: Chemotherapy, Vol. 33, No. 2, 01.01.1987, p. 151-156.

Research output: Contribution to journalArticle

Leonard, M. F. ; Kumar, A. ; Murray, Dennis L ; Beaman, D. C. / Inhibitory effect of Azone® (1-dodecylazacycloheptan-2-one) on herpes simplex virus. In vivo and in vitro studies. In: Chemotherapy. 1987 ; Vol. 33, No. 2. pp. 151-156.
@article{541de468067f4de5b6c6014dc3469e06,
title = "Inhibitory effect of Azone{\circledR} (1-dodecylazacycloheptan-2-one) on herpes simplex virus. In vivo and in vitro studies",
abstract = "Enhanced activity of antiviral agents, when mixed with a penetration enhancer like Azone{\circledR} (1-dodecylazacycloheptan-2-one) in topical preparations, is well-recognized. These studies were undertaken to investigate whether Azone, per se, has any activity against herpes simplex (HSV) type 1 and type 2 viruses. When HSV-1 and HSV-2 were mixed with 5, 10 and 20{\%} Azone, there was a 1-4.5 log 10 decrease in virus titers. The efficacy of 5 and 10{\%} Azone applied topically was evaluated during the treatment of HSV-1 cutaneous infections in guinea pigs. HSV-1 infection was produced by intradermally inoculating guinea pigs with 10 7.7 HSV-l/ml. The mean number of lesions per site was reduced by more than 50{\%} in Azone-treated sites as compared to no treatment (control) sites (p < 0.01). Similarly, the surface area of each lesion in the Azone-treated sites was only 40{\%} of that seen in control sites (p < 0.001). More than 80{\%} of the lesions on Azone-treated sites healed by day 4 as compared to only 3{\%} on control sites (p < 0.001). These data indicate that Azone, a lipophilic chemical, may have antiviral properties when used topically.",
author = "Leonard, {M. F.} and A. Kumar and Murray, {Dennis L} and Beaman, {D. C.}",
year = "1987",
month = "1",
day = "1",
doi = "10.1159/000238487",
language = "English (US)",
volume = "33",
pages = "151--156",
journal = "Chemotherapy",
issn = "0009-3157",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Inhibitory effect of Azone® (1-dodecylazacycloheptan-2-one) on herpes simplex virus. In vivo and in vitro studies

AU - Leonard, M. F.

AU - Kumar, A.

AU - Murray, Dennis L

AU - Beaman, D. C.

PY - 1987/1/1

Y1 - 1987/1/1

N2 - Enhanced activity of antiviral agents, when mixed with a penetration enhancer like Azone® (1-dodecylazacycloheptan-2-one) in topical preparations, is well-recognized. These studies were undertaken to investigate whether Azone, per se, has any activity against herpes simplex (HSV) type 1 and type 2 viruses. When HSV-1 and HSV-2 were mixed with 5, 10 and 20% Azone, there was a 1-4.5 log 10 decrease in virus titers. The efficacy of 5 and 10% Azone applied topically was evaluated during the treatment of HSV-1 cutaneous infections in guinea pigs. HSV-1 infection was produced by intradermally inoculating guinea pigs with 10 7.7 HSV-l/ml. The mean number of lesions per site was reduced by more than 50% in Azone-treated sites as compared to no treatment (control) sites (p < 0.01). Similarly, the surface area of each lesion in the Azone-treated sites was only 40% of that seen in control sites (p < 0.001). More than 80% of the lesions on Azone-treated sites healed by day 4 as compared to only 3% on control sites (p < 0.001). These data indicate that Azone, a lipophilic chemical, may have antiviral properties when used topically.

AB - Enhanced activity of antiviral agents, when mixed with a penetration enhancer like Azone® (1-dodecylazacycloheptan-2-one) in topical preparations, is well-recognized. These studies were undertaken to investigate whether Azone, per se, has any activity against herpes simplex (HSV) type 1 and type 2 viruses. When HSV-1 and HSV-2 were mixed with 5, 10 and 20% Azone, there was a 1-4.5 log 10 decrease in virus titers. The efficacy of 5 and 10% Azone applied topically was evaluated during the treatment of HSV-1 cutaneous infections in guinea pigs. HSV-1 infection was produced by intradermally inoculating guinea pigs with 10 7.7 HSV-l/ml. The mean number of lesions per site was reduced by more than 50% in Azone-treated sites as compared to no treatment (control) sites (p < 0.01). Similarly, the surface area of each lesion in the Azone-treated sites was only 40% of that seen in control sites (p < 0.001). More than 80% of the lesions on Azone-treated sites healed by day 4 as compared to only 3% on control sites (p < 0.001). These data indicate that Azone, a lipophilic chemical, may have antiviral properties when used topically.

UR - http://www.scopus.com/inward/record.url?scp=0023158685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023158685&partnerID=8YFLogxK

U2 - 10.1159/000238487

DO - 10.1159/000238487

M3 - Article

C2 - 3032527

AN - SCOPUS:0023158685

VL - 33

SP - 151

EP - 156

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3157

IS - 2

ER -